GPC Biotech appoints Dr. Marcel Rozencweig as Senior Vice President of drug development

22-May-2001

GPC Biotech (Frankfurt Stock Exchange: GPC) today announced a key addition to its drug development capabilities through the appointment of Marcel Rozencweig, M.D. as Senior Vice President of Drug Development. Dr. Rozencweig's primary responsibilities will include the acceleration of the company's drug development programs and the expansion of its portfolio through in-licensing of new clinical compounds in core therapeutic areas. GPC Biotech is currently pursuing nine internal product programs in oncology, infectious diseases and immunology.

Prior to joining GPC Biotech, Dr. Rozencweig held several senior leadership positions in drug development and strategic planning at Bristol-Myers Squibb, including the position of Vice President, Oncology, Infectious Diseases and Immunology Clinical Research in which he was responsible for all of Bristol-Myers Squibb's clinical research and development programs in these therapeutic areas. Prior to his leading role in clinical research and development, Dr. Rozencweig was Vice President, Anticancer Research. His most recent position at Bristol-Myers Squibb was Vice President, Strategic Planning and Portfolio Management.

Over his 18-year career, Dr. Rozencweig has established himself as an expert in several areas, including pharmaceutical R&D, worldwide clinical R&D, strategic planning, portfolio management and development, particularly focused in GPC Biotech's core drug development areas of oncology, immunology and infectious diseases. During his tenure at Bristol-Myers Squibb he brought numerous products into human clinical trials and more than 10 NCE's (New Chemical Entities) through FDA approval and to market. Among his many R&D achievements are significant contributions leading to the successful FDA approval of numerous anticancer treatments including Taxol (paclitaxel), Paraplatin (carboplatin), and VePesid (etoposide). Dr. Rozencweig serves on the advisory board of New York University Cancer Center and New Jersey Cancer Center, is a member of 13 Medical Societies and 9 Editorial Boards and has authored or co-authored more than 200 papers.

Bernd R. Seizinger, M.D., Ph.D., President and CEO of GPC Biotech said: "I am delighted to welcome Dr. Marcel Rozencweig to GPC Biotech. One of our company's key strategic aims is to build a comprehensive clinical drug development portfolio in oncology, immunology, and infectious disease based upon our proprietary genomics and proteomics technologies. Dr. Rozencweig's tremendous experience in bringing products through the clinic in these core therapeutic areas makes him a perfect fit for the next phase in the development and forward integration of GPC Biotech."

Marcel Rozencweig, M.D., said, "GPC Biotech is poised to become one of the premier companies able to create novel therapeutics by integrating genomics and proteomics technologies into drug discovery and development. I am excited to be joining a company of such energy and vision, and I very much look forward to working together with GPC Biotech's dynamic scientific and management team."

https://www.chemeurope.com/en/news/3257/gpc-biotech-appoints-dr-marcel-rozencweig-as-senior-vice-president-of-drug-development.html